Wang Wei: a pathfinder of xenotransplantation

Categories:Enterprise dynamics
Author:
Origin:
Time of issue:2020-03-19 16:35
Views:

(Summary description)GuangmingDailyreporterlongJunyuAihua The36yearoldmaXiaojun(pseudonym)suffersfromtypeIdiabetes.Ifheeatsacorn,hisbloodsugarwillexceedthestandard.Heneedstotakealargedoseofinsulineverydaytoreducehisbloodsugar.AfterreceivingislettransplantationinXiangyathirdhospitalaofCentralSouthUniversity,MaXiaojun'sinsulininjectiondecreasedby80%,hislifereturnedtonormal,andhewasabletogoouttowork. "Hownicetoliveeasily!"MaXiaojunsaidthatthankstoProfessorWangWeiforallthis. WangWeiisaradiologistintheThirdXiangyaHospital.Hislong-termclinicalexperiencehasmadehimknowthatthepaincausedbydiabetesishardforordinarypeopletoimagine.TypeIdiabetesisthemostdifficult.Becauseoftheunstablebloodglucose,itwillleadtoavarietyoflife-threateningcomplications. Islettransplantationisoneofthemostlikelymethodstocurediabetes.However,theextremeshortageofhumandonorsmakesthispossibilitymoreandmoreremote. Canweusetheinterventionmethodtotreatdiabetesmellituswithisletcelltransplantationofanimalsotherthanhuman?Medicalscientistsallovertheworldgraduallyfocusonanimals,especiallypigs.Theresultsshowthatthereisonlyoneaminoacidinpiginsulinmoleculewhichisdifferentfromhumaninsulin,whichmakespigisletxenotransplantationthemostlikelycurefordiabetesintheworldandthehopeoflarge-scaleapplication. In1995,WangWeidecidedtoturntoxenotransplantation.Inthisyear,XiangyaThirdHospitalsupportedWangWei's100000yuanscientificresearchfund,launchedthepreliminaryresearchofislettransplantation,andestablishedtheislettransplantationlaboratory.Sincethen,WangWeibegantodevotehimselftotheresearchonthetreatmentofdiabetesbyislettransplantation,andtheresearchgrouphasalsobecomeoneoftheinternationalacademicteamsthatfirstcarriedoutrelevantresearch. (isletcells) After4yearsofresearch,WangWei'steamachievedabreakthroughinthetreatmentofdiabetesbyintrahepatictransplantationofporcinepancreaticislandcellsviahepaticartery.WiththeapprovaloftheformerMinistryofhealth,WangWei'steamcompleted22clinicaltrialsof"pighuman"islettransplantationindiabetespatientsfrom2000to2004,andachievedsignificanttherapeuticeffects.Theresultsshowedthattheinsulinuseof20patientswasreducedbymorethan30%,whichwas"effective";6of20patientswerereducedbymorethan50%,whichwas"significanteffect";oneofthemwas"temporarilycured"foroneweek. In2005,WangWei'steamalsoachievedthreemajorbreakthroughs:creatingasafermethodofliverarterytransplantationinsteadofportalveinimplantation,findingobviousdifferencesinsideeffectsamongdifferenthumanspeciesinantirejectiontreatment,andexploringdifferentantirejectiontreatmentmethodsinxenotransplantationandhomotransplantationofisletsofLangerhans.InMayofthesameyear,WangWei'sClinicalResearchReportonthetreatmentoftypeIdiabetesmellituswithporcineisletcelltransplantationwashighlypraisedatthe9thAnnualMeetingoftheInternationalAssociationofpancreasislettransplantationheldinGeneva,Switzerland.InAugust,ProfessorCarlgross,whowasthechairmanoftheNobelPrizeforphysiologicalmedicine,praisedWangWeiforhis"pioneeringwork". Therearetoomanyhardshipsandsweatbehindthehalo. Inordertofindthemostsuitablepigprovenance,WangWeiwentuptotheQinghaiTibetPlateauinthenorthanddowntoHainanIslandinthesouth,andscreeneddozensofpigprovenancesinremotevillagesinmorethantenprovinces.Inrecentyears,WangWeihastraveledtensofthousandsofmiles,collectedandstudied11uniquepurepigbreedsinChina,selectedthemostsuitablepigsourcefortransplantation,andestablishedtwoinitialpigsourcebasesinHunanProvince. (xenograftdonorpig) Attheendof2012,WangWei'steamestablishedtheworld'ssecondDPFdonorpigbreedingcenterinChangsha.In2013,theclinicalstudyofxenotransplantationofisletsofLangerhanswasapprovedbythecompetentdepartmentofthegovernment.In2016,itpassedthemid-termreviewoftherapeuticeffectbyexpertsorganizedbythehealthandFamilyPlanningCommissionofHunanProvince.In2017,itpassedthefinalreviewoftherapeuticeffectbyexpertsorganizedbythehealthandFamilyPlanningCommissionofHunanProvince.Thismeansthatxenotransplantationcanfinallyentertheclinicalpractice,benefitingtensofmillionsofordinarypatients. Withtheproblemofscientificresearchbeingsolvedonebyone,abiggerproblemappearedinfrontofWangWei,thatis,thenorm.TheconscienceandsenseofresponsibilityofscientistsalwaysremindWangWeithatxenotransplantationisamajorsubjectandhasgreatbusinessopportunities.Withoutaunifiedandstrictinternationalstandard,itisverydangerousandcontrarytotheoriginalintentionofscientificresearch. Atthebeginningof2006,WangWeistartedthetransformationandinnovationfromthepuretechnicalandtheoreticalresearchofxenotransplantationtotherelatedresearchofestablishinginternationalstandardizedpreclinicalresearchofxenotransplantation,andtooktheleadintheinvestigationofformulatingxenotransplantationnormsinChina.InNovember2008,the"InternationalSymposiumonclinicalresearchnormsofglobalxenotransplantation"washeldinXiangyaThirdHospital,whichformulatedtheChangshadeclaration,aglobalxenotransplantationprogrammaticdocument.Forthefirsttime,theinternationalmedicalclinicalnormswerebrandedwith"Chinesestamp". (Changshadeclaration) InDecember2018,theThirdWorldHealthOrganizationSymposium

Wang Wei: a pathfinder of xenotransplantation





Wang Wei: a pathfinder of xenotransplantation

(Summary description)GuangmingDailyreporterlongJunyuAihua The36yearoldmaXiaojun(pseudonym)suffersfromtypeIdiabetes.Ifheeatsacorn,hisbloodsugarwillexceedthestandard.Heneedstotakealargedoseofinsulineverydaytoreducehisbloodsugar.AfterreceivingislettransplantationinXiangyathirdhospitalaofCentralSouthUniversity,MaXiaojun'sinsulininjectiondecreasedby80%,hislifereturnedtonormal,andhewasabletogoouttowork. "Hownicetoliveeasily!"MaXiaojunsaidthatthankstoProfessorWangWeiforallthis. WangWeiisaradiologistintheThirdXiangyaHospital.Hislong-termclinicalexperiencehasmadehimknowthatthepaincausedbydiabetesishardforordinarypeopletoimagine.TypeIdiabetesisthemostdifficult.Becauseoftheunstablebloodglucose,itwillleadtoavarietyoflife-threateningcomplications. Islettransplantationisoneofthemostlikelymethodstocurediabetes.However,theextremeshortageofhumandonorsmakesthispossibilitymoreandmoreremote. Canweusetheinterventionmethodtotreatdiabetesmellituswithisletcelltransplantationofanimalsotherthanhuman?Medicalscientistsallovertheworldgraduallyfocusonanimals,especiallypigs.Theresultsshowthatthereisonlyoneaminoacidinpiginsulinmoleculewhichisdifferentfromhumaninsulin,whichmakespigisletxenotransplantationthemostlikelycurefordiabetesintheworldandthehopeoflarge-scaleapplication. In1995,WangWeidecidedtoturntoxenotransplantation.Inthisyear,XiangyaThirdHospitalsupportedWangWei's100000yuanscientificresearchfund,launchedthepreliminaryresearchofislettransplantation,andestablishedtheislettransplantationlaboratory.Sincethen,WangWeibegantodevotehimselftotheresearchonthetreatmentofdiabetesbyislettransplantation,andtheresearchgrouphasalsobecomeoneoftheinternationalacademicteamsthatfirstcarriedoutrelevantresearch. (isletcells) After4yearsofresearch,WangWei'steamachievedabreakthroughinthetreatmentofdiabetesbyintrahepatictransplantationofporcinepancreaticislandcellsviahepaticartery.WiththeapprovaloftheformerMinistryofhealth,WangWei'steamcompleted22clinicaltrialsof"pighuman"islettransplantationindiabetespatientsfrom2000to2004,andachievedsignificanttherapeuticeffects.Theresultsshowedthattheinsulinuseof20patientswasreducedbymorethan30%,whichwas"effective";6of20patientswerereducedbymorethan50%,whichwas"significanteffect";oneofthemwas"temporarilycured"foroneweek. In2005,WangWei'steamalsoachievedthreemajorbreakthroughs:creatingasafermethodofliverarterytransplantationinsteadofportalveinimplantation,findingobviousdifferencesinsideeffectsamongdifferenthumanspeciesinantirejectiontreatment,andexploringdifferentantirejectiontreatmentmethodsinxenotransplantationandhomotransplantationofisletsofLangerhans.InMayofthesameyear,WangWei'sClinicalResearchReportonthetreatmentoftypeIdiabetesmellituswithporcineisletcelltransplantationwashighlypraisedatthe9thAnnualMeetingoftheInternationalAssociationofpancreasislettransplantationheldinGeneva,Switzerland.InAugust,ProfessorCarlgross,whowasthechairmanoftheNobelPrizeforphysiologicalmedicine,praisedWangWeiforhis"pioneeringwork". Therearetoomanyhardshipsandsweatbehindthehalo. Inordertofindthemostsuitablepigprovenance,WangWeiwentuptotheQinghaiTibetPlateauinthenorthanddowntoHainanIslandinthesouth,andscreeneddozensofpigprovenancesinremotevillagesinmorethantenprovinces.Inrecentyears,WangWeihastraveledtensofthousandsofmiles,collectedandstudied11uniquepurepigbreedsinChina,selectedthemostsuitablepigsourcefortransplantation,andestablishedtwoinitialpigsourcebasesinHunanProvince. (xenograftdonorpig) Attheendof2012,WangWei'steamestablishedtheworld'ssecondDPFdonorpigbreedingcenterinChangsha.In2013,theclinicalstudyofxenotransplantationofisletsofLangerhanswasapprovedbythecompetentdepartmentofthegovernment.In2016,itpassedthemid-termreviewoftherapeuticeffectbyexpertsorganizedbythehealthandFamilyPlanningCommissionofHunanProvince.In2017,itpassedthefinalreviewoftherapeuticeffectbyexpertsorganizedbythehealthandFamilyPlanningCommissionofHunanProvince.Thismeansthatxenotransplantationcanfinallyentertheclinicalpractice,benefitingtensofmillionsofordinarypatients. Withtheproblemofscientificresearchbeingsolvedonebyone,abiggerproblemappearedinfrontofWangWei,thatis,thenorm.TheconscienceandsenseofresponsibilityofscientistsalwaysremindWangWeithatxenotransplantationisamajorsubjectandhasgreatbusinessopportunities.Withoutaunifiedandstrictinternationalstandard,itisverydangerousandcontrarytotheoriginalintentionofscientificresearch. Atthebeginningof2006,WangWeistartedthetransformationandinnovationfromthepuretechnicalandtheoreticalresearchofxenotransplantationtotherelatedresearchofestablishinginternationalstandardizedpreclinicalresearchofxenotransplantation,andtooktheleadintheinvestigationofformulatingxenotransplantationnormsinChina.InNovember2008,the"InternationalSymposiumonclinicalresearchnormsofglobalxenotransplantation"washeldinXiangyaThirdHospital,whichformulatedtheChangshadeclaration,aglobalxenotransplantationprogrammaticdocument.Forthefirsttime,theinternationalmedicalclinicalnormswerebrandedwith"Chinesestamp". (Changshadeclaration) InDecember2018,theThirdWorldHealthOrganizationSymposium

Categories:Enterprise dynamics
Author:
Origin:
Time of issue:2020-03-19 16:35
Views:

Guangming Daily reporter long Junyu Aihua

The 36 year old ma Xiaojun (pseudonym) suffers from type I diabetes. If he eats a corn, his blood sugar will exceed the standard. He needs to take a large dose of insulin every day to reduce his blood sugar. After receiving islet transplantation in Xiangya third hospital a of Central South University, Ma Xiaojun's insulin injection decreased by 80%, his life returned to normal, and he was able to go out to work.

"How nice to live easily!" Ma Xiaojun said that thanks to Professor Wang Wei for all this.

Wang Wei is a radiologist in the Third Xiangya Hospital. His long-term clinical experience has made him know that the pain caused by diabetes is hard for ordinary people to imagine. Type I diabetes is the most difficult. Because of the unstable blood glucose, it will lead to a variety of life-threatening complications.

Islet transplantation is one of the most likely methods to cure diabetes. However, the extreme shortage of human donors makes this possibility more and more remote.

Can we use the intervention method to treat diabetes mellitus with islet cell transplantation of animals other than human? Medical scientists all over the world gradually focus on animals, especially pigs. The results show that there is only one amino acid in pig insulin molecule which is different from human insulin, which makes pig islet xenotransplantation the most likely cure for diabetes in the world and the hope of large-scale application.

In 1995, Wang Wei decided to turn to xenotransplantation. In this year, Xiangya Third Hospital supported Wang Wei's 100000 yuan scientific research fund, launched the preliminary research of islet transplantation, and established the islet transplantation laboratory. Since then, Wang Wei began to devote himself to the research on the treatment of diabetes by islet transplantation, and the research group has also become one of the international academic teams that first carried out relevant research.

(islet cells)

After 4 years of research, Wang Wei's team achieved a breakthrough in the treatment of diabetes by intrahepatic transplantation of porcine pancreatic island cells via hepatic artery. With the approval of the former Ministry of health, Wang Wei's team completed 22 clinical trials of "pig human" islet transplantation in diabetes patients from 2000 to 2004, and achieved significant therapeutic effects. The results showed that the insulin use of 20 patients was reduced by more than 30%, which was "effective"; 6 of 20 patients were reduced by more than 50%, which was "significant effect"; one of them was "temporarily cured" for one week.

In 2005, Wang Wei's team also achieved three major breakthroughs: creating a safer method of liver artery transplantation instead of portal vein implantation, finding obvious differences in side effects among different human species in anti rejection treatment, and exploring different anti rejection treatment methods in xenotransplantation and homotransplantation of islets of Langerhans. In May of the same year, Wang Wei's Clinical Research Report on the treatment of type I diabetes mellitus with porcine islet cell transplantation was highly praised at the 9th Annual Meeting of the International Association of pancreas islet transplantation held in Geneva, Switzerland. In August, Professor Carl gross, who was the chairman of the Nobel Prize for physiological medicine, praised Wang Wei for his "pioneering work".

There are too many hardships and sweat behind the halo.

In order to find the most suitable pig provenance, Wang Wei went up to the Qinghai Tibet Plateau in the north and down to Hainan Island in the south, and screened dozens of pig provenances in remote villages in more than ten provinces. In recent years, Wang Wei has traveled tens of thousands of miles, collected and studied 11 unique pure pig breeds in China, selected the most suitable pig source for transplantation, and established two initial pig source bases in Hunan Province.

(xenograft donor pig)

At the end of 2012, Wang Wei's team established the world's second DPF donor pig breeding center in Changsha. In 2013, the clinical study of xenotransplantation of islets of Langerhans was approved by the competent department of the government. In 2016, it passed the mid-term review of therapeutic effect by experts organized by the health and Family Planning Commission of Hunan Province. In 2017, it passed the final review of therapeutic effect by experts organized by the health and Family Planning Commission of Hunan Province. This means that xenotransplantation can finally enter the clinical practice, benefiting tens of millions of ordinary patients.

With the problem of scientific research being solved one by one, a bigger problem appeared in front of Wang Wei, that is, the norm. The conscience and sense of responsibility of scientists always remind Wang Wei that xenotransplantation is a major subject and has great business opportunities. Without a unified and strict international standard, it is very dangerous and contrary to the original intention of scientific research.

At the beginning of 2006, Wang Wei started the transformation and innovation from the pure technical and theoretical research of xenotransplantation to the related research of establishing international standardized pre clinical research of xenotransplantation, and took the lead in the investigation of formulating xenotransplantation norms in China. In November 2008, the "International Symposium on clinical research norms of global xenotransplantation" was held in Xiangya Third Hospital, which formulated the Changsha declaration, a global xenotransplantation programmatic document. For the first time, the international medical clinical norms were branded with "Chinese stamp".

(Changsha declaration)

In December 2018, the Third World Health Organization Symposium on clinical research norms of xenotransplantation was held in Changsha, Hunan Province, which formed the Changsha declaration 2018. Chinese experts represented by Wang Wei have played an important role in the implementation of Changsha declaration in the field of xenotransplantation and the innovative research results.

"I hope that in the future, xenotransplantation will not only eradicate diabetes with pig islet cells, but also industrialize and standardize the production of transplant organs, realize large organ transplantation such as kidney and heart, and make it the ultimate solution for many human malignant diseases," Wang said

Scan the QR code to read on your phone

Previous: Professor Wang Wei's team of Xiangya Third Hospital of Central South University won another good performance at the World Conference on xenotransplantation

Next: Optipharm: using the technology of different islets of Langerhans to seize the market of biological agents for diabetes treatment in China

Previous: Professor Wang Wei's team of Xiangya Third Hospital of Central South University won another good performance at the World Conference on xenotransplantation

Next: Optipharm: using the technology of different islets of Langerhans to seize the market of biological agents for diabetes treatment in China